Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Sees Decades-Long Time Horizon For Novel Antibiotics

Executive Summary

Merck is one of the few big pharmas still investing in early-stage antibiotic R&D and is focusing long term on novel antibody and small molecule approaches, but Infectious Disease Research VP Daria Hazuda predicts the timeline for delivering innovative breakthroughs will be long.

Advertisement

Related Content

Merck & Co Expands C Diff Franchise With US Zinplava Approval
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
Cubist’s Zerbaxa Approval Marks Firm’s Second Novel Antibiotic In 2014
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Market Snapshot: Gram-Negative Antibiotics Progress As Urgency Grows

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel